Overview

A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

This study will determine whether an oral drops formulation of triazolam at a dose of 0.25 mg is bioequivalent to a tablet formulation at a dose of 0.25 mg in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Triazolam